Dear Editor,

Burkitt lymphoma/leukemia (BL/L) was the first neoplasia associated with rearrangement in *MYC* that is the molecular hallmark of this disease. Particularly, immunoglobulin genes are associated with *MYC* in BL/L, where the juxtaposition with heavy chain locus (14q32) or light chain loci (2p12 and 22q11) leads to *MYC* overexpression, which is believed to play a central role in BL/L pathogenesis \[[@B1]\].

During investigation of the clinical significance of secondary chromosomal abnormalities in pediatric BL/L, we identified a patient with BL/L without detectable *MYC* translocation \[[@B2]\]. Here, we aimed to refine cytogenetic and molecular characteristics, such as expression levels of *MYC*, other genes, and microRNAs, to contribute to the diagnosis of BL/L without *MYC* translocations. Clinical data are described in [Table 1](#T1){ref-type="table"}.

G-banding of bone marrow (BM) cells revealed 46,XY,der(8) in 31.5% of the metaphases analyzed ([Fig. 1A](#F1){ref-type="fig"}). FISH analysis revealed three *MYC* signals, two in the derivative chromosome 8, apart from a normal chromosome 8 ([Fig. 1B, C](#F1){ref-type="fig"}). FISH analysis of *BCL6* and *BCL2* loci ruled out abnormalities common to other B cell non-Hodgkin lymphomas (NHL) ([Fig. 1D](#F1){ref-type="fig"}). Multicolor FISH excluded the presence of any other chromosomal abnormality, including changes in chromosome 11, recently associated with *MYC*-negative BL/L cases in the WHO classification \[[@B3]\]. Multicolor probes helped define the final karyotype as 46,XY,der(8)t(8;8)(qter-\>q21::p22-\>qter) ([Fig. 1E, F](#F1){ref-type="fig"}).

In 2006, Hummel et al \[[@B4]\] proposed a molecular signature for BL/L, including in their sample cases with lymphomas lacking *MYC* rearrangement. Among them, *CD10* and *BCL2*, besides *MYC*, were found to be differentially expressed and are used as classifiers for BL/L signature. Moreover, supporting the idea of *MYC* post-transcriptional deregulation in BL/L, some studies have revealed differential expression patterns of specific miRNAs in comparison to that in other NHL \[[@B5][@B6]\]. For molecular characterization, tumor samples from four patients with BL/L harboring t(8;14)(q24;q32) (median age, nine years; BCL6-positive and BCL2-negative), cells from three BL and two diffuse large B-cell lymphoma cell lines, three reactive follicular hyperplasia lymph nodes, and two normal BM samples were used for comparison.

*MYC* and *BCL2* expression levels in our patient were similar to those in the BL/L group, although *BCL2* levels were lower than those observed in all the cases with BL/L ([Fig. 1G, H](#F1){ref-type="fig"}). Similarly, *CD10* levels were lower than those in the BL/L group ([Fig. 1I](#F1){ref-type="fig"}). These differences are likely to have arisen from the different types of samples used for molecular testing. miR155 and Let7a, 7b, and 7e, which are downregulated by *MYC* \[[@B7]\], were in general at low levels in the BL/L group ([Fig. 1J--M](#F1){ref-type="fig"}). miR9\*, usually downregulated in patients lacking the *MYC* translocation \[[@B6]\], was downregulated in our patient as well as in the BL/L group ([Fig. 1N](#F1){ref-type="fig"}). miR150 and miR21 were downregulated in all the cases ([Fig. 1O--P](#F1){ref-type="fig"}) \[[@B7]\]. Thus, gene expression analysis of our patient suggests a BL-like molecular profile despite the lack of *MYC* translocation.

To the best of our knowledge, this is the first report on a patient with a partial trisomy 8 lacking the typical t(8;14)(q24;q32), which resulted in three copies of *MYC*, and *MYC* overexpression was comparable to that generally found in BL/L. In rare cases, *MYC* rearrangement cannot be identified \[[@B1][@B5]\], and the gene expression profile appears to be comparable to that observed in BL/L \[[@B4]\]. This suggests that other pathogenic mechanisms could lead to deregulation, such as post-transcriptional control by microRNA, of *MYC* expression \[[@B5][@B6]\]. In this context, since 2008, the WHO classification includes BL/L cases without a demonstrable MYC translocation \[[@B3]\].

Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder associated with an elevated risk (10--30%) of developing malignancies. NHL was the most frequently detected cancer (53--64%) in patients with A-T \[[@B8]\]; however, BL/L is rarely reported. Despite its rarity, Sandlund et al \[[@B9]\] suggested that BL/L in patients with A-T tends to carry non-canonical *MYC* rearrangements, probably because of global chromosome instability. This hypothesis is in agreement with that observed in our patient.

In summary, our results, obtained using molecular cytogenetics and expression approaches, add new information about BL/L without *MYC* translocation. Whether the altered *MYC* expression in our patient resulted from microRNA deregulation, a known alternative pathogenic mechanism \[[@B5][@B6]\], or from trisomy 8, which might result in *MYC* overexpression by an increased gene dosage, remains to be elucidated.
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![Cytogenetics and molecular characterization. (A) G-banding cytogenetics: GTG banding karyotype showing the derivative chromosome 8 pointed by the red arrow. (B--F) Molecular cytogenetics: (B) FISH analysis using *IGH/MYC/CEP8* Tri-Color Dual Fusion Probe (04N10-020, Abbott Molecular, Des Plaines, IL, USA). Green signal: *IGH*; red signal: *MYC*; aqua signal: CEP8; (C) LSI *MYC* Spectrum Orange Probe (02N22-020, Abbott Molecular) shows derivative chromosome 8 with 2 copies of *MYC*, 3 in total per cell; (D) Complementary FISH analyses using *BCL6* Break Apart Probe (Z-2177-50, ZytoVision GmbH, Bremerhaven, HB, DE) and *BLC2* Break Apart Probe (Z-2192-50, ZytoVision GmbH) showed normal partners for both chromosomes 3 and 18, respectively; (E) FISH using partial chromosome paintings for 8p and 8q arms showed partial trisomy 8; (F) Multicolor chromosome banding probe for chromosome 8 characterized the derivative chromosome 8 as a result of t(8;8)(pter-\>q21::p22-\>qter); (G--P) Comparisons between cellular genes and microRNA (miRNA) expressions among our patient and classical Burkitt lymphomas, healthy bone marrow (BM) cells, reactive follicular hyperplasias (RFH), and BL- and diffuse large B-cell lymphoma (DLBCL)-derived cell lines. (G) *MYC*; (H) *BCL2*; (I) *CD10*; (J) miR-155; (K) miR-Let7a; (L) miR-Let7b; (M) miR-Let7e; (N) miR-9\*; (O) miR-150; (P) miR-21. Case: study patient; BL: classical Burkitt lymphoma; BL-CL: represent the mean values of BL-derived cell lines---Namalwa, Raji, and Ramos; DLBCL-CL: represents the mean values of diffuse large B-cell lymphoma (DLBCL)-derived cell lines---Farage and Pfeiffer; BM: bone marrow cells from healthy donors; RFH: reactive follicular hyperplasia of lymph nodes. The line set at 1 represents the calibration reference. RNA was extracted from FFPE BM biopsy (case) and BL and RFH lymph node using MasterPure™ RNA Purification Kit (Epicentre, Madison, WI, USA). RNA from BM and cell lines was extracted with Direct-zol™ RNA MiniPrep (Zymo Research, Irvine, CA, USA). Relative expression of *CD10* and *BCL2* was evaluated by TaqMan® assays, as previously described \[[@B10]\], using the average of *ACTB* and *B2M* reference genes for normalization. *MYC* expression was quantified with SYBR green® assays using the average of *ACTB* and *GUSB* for normalization. miRNAs were quantified with stem-loop TaqMan® assays (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) after reverse transcription with MicroRNA Reverse Transcription Kit (Applied Biosystems, Life Technologies) for each miRNA and the reference small RNA RNU48. Quantification values were expressed as fold change (2^−ΔΔCq^) after calibration with the classical BL sample exhibiting the lowest expression level. Bars represent the mean of fold change values in each category, except for the case, in which the mean of two different experiments was represented. Error bars represent standard error of the mean.](alm-38-63-g001){#F1}

###### Clinical characteristics of the patient

![](alm-38-63-i001)

  Clinical parameters                      Case features
  ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age and gender                           7 years, male
  History                                  4 months of vomiting, diarrhea, fever, sweating, weight loss; 10 days of joint pain; abdominal mass (6 cm); genetically and clinically diagnosed with AT at the age of 18 months with the use of gamma aminobutyric acid for 3 years for treatment and control of ataxia.
  Adenomegalies                            Hepatomegaly (3 cm)
  WBC count                                6.1 × 10^9^/L
  Platelet count                           534.0 × 10^9^/L
  LDH                                      2,378 U/L
  BM morphology and immunohistochemistry   Hypercellularity; 92% of the lymphoid blasts with basophilic cytoplasm and vacuoles characteristic of L3 (BL/L) morphology; CD20+, EMA−, CD3−, CD99−, Myeloperoxidase−, TDT−, BCL2−
  BM immunophenotype (flow cytometry)      Positive for: HLA-Dr, CD20, CD22, CD45, CD19, CD38, CD79b, cCD79a, sIgκ, IgM. Negative for: CD8, CD5, CD13, CD33, CD34, CD23, CD15, TdT
  Protocol                                 BFM-95 for BL/L modified for the treatment of AT (ICD: 10 G11.3) associated NHL
  Clinical outcome                         Relapse 5 months after initial diagnosis and death by disease progression

Abbreviations: cm, centimeters; AT, ataxia-telangiectasia; L, liter; U/L, units per liter; WBC, white blood cell; LDH, lactate dehydrogenase; BM, bone marrow; BL/L, Burkitt lymphoma/leukemia; BFM-95, Berlin, Frankfurt and Munster 95 protocol; ICD, International Classification of Diseases; NHL, non-Hodgkin lymphoma.
